CRISPR Therapeutics AG CRSP
NASDAQ · United States · Health Technology
$55.32-0.68 (-1.21%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Fisher’s new positions were small, but they overlap with two sizable ARK holdings in crypto infrastructure and gene editing.
AbbVie has scaled its post-Humira growth engine, while CRISPR Therapeutics is turning Casgevy into a higher-risk commercial opportunity.